Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Alumis Inc. Common StockNASDAQ: ALMS
Net Margin · Q2 FY2026 · quarter ended Jun 2026
Net margin narrows to -8557.2%
Net margin was -8557.2% in Q2 FY2026, down 10782.3 pp from a year earlier. On a trailing-twelve-month basis it was -5933.5%, down 4799.0 pp year over year.
What to watch
Whether net margin reaches the consensus estimate from 8 analysts of -38541.6% for the fiscal year ending Dec 2026, down from -1011.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -8557.2%-3212.4 pp QoQ
- Last fiscal yearDec 2025
- -1011.7%— YoY
- LTMJun 2026
- -5933.5%-4799.0 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -10782.3 pp | +202.6 pp | +10984.9 pp |
| 1 year | — | -37529.8 pp | — |
| 3 years | — | -17.6 pp | — |
| 5 years | +1190.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1011.7%
- Year-over-year change
- —
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1011.7% | — |
| FY2024 | 2024-12-31 | — | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
Net Margin vs competitors
How ALMS compares with its peers on the latest reported figures
- ALMS's LTM Jun 2026 net margin of -5933.5% is the 4th highest of the 6 companies compared; the peer median is -832.6%.
- Its year-over-year change of -4799.0 pp is the 4th highest of 6, against a peer median of -100.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 121.5% | +103.2 pp | +173.4 pp | |
| LTM Mar 2026 | -11.5% | +114.2 pp | +1245.7 pp | |
| LTM Mar 2026 | -832.6% | -100.2 pp | -537.5 pp | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -5933.5% | -4799.0 pp | — |
| LTM Mar 2026 | -143627.1% | -160183.1 pp | -132411.6 pp | |
| LTM Mar 2026 | -146303.9% | -111837.5 pp | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ALMS) | -832.6% | -100.2 pp | -182.0 pp | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 24.05M |
| Cost of Revenue | 250K | 0 | 3.15M | 3.5M |
| Gross Profit | (250K) | 0 | (3.15M) | 20.55M |
| Gross Margin | — | — | — | 85.5% |
| Research & Development | 101.05M | 137.68M | 265.55M | 386M |
| Selling, General & Admin | 12.55M | 20.5M | 35.2M | 91.86M |
| Operating Expenses | 113.6M | 158.17M | 297.6M | 447.76M |
| Depreciation & Amortization | 250K | 1.28M | 3.15M | 3.5M |
| EBITDA | (111.68M) | (153.71M) | (291.08M) | (248.39M) |
| EBITDA Margin | — | — | — | -1032.8% |
| Operating Income | (113.85M) | (158.17M) | (300.75M) | (427.2M) |
| Operating Margin | — | — | — | -1776.3% |
| Interest Income | 1.99M | 3.37M | 12.02M | 14.18M |
| Interest Expense | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | 3.18M | 6.52M | 175.32M |
| Income Before Tax | (111.93M) | (154.99M) | (294.23M) | (251.89M) |
| Pre-Tax Margin | — | — | — | -1047.3% |
| Income Tax Expense | 0 | 0 | 0 | (8.56M) |
| Net Income | (111.93M) | (154.99M) | (294.23M) | (243.33M) |
| Net Margin | — | — | — | -1011.7% |
| EPS (Basic) | (14.93) | (2.99) | (10.38) | (2.32) |
| EPS (Diluted) | (14.93) | (2.99) | (10.38) | (2.32) |
| Weighted Avg Shares | 7.5M | 51.84M | 28.34M | 850.3M |
| Weighted Avg Shares (Diluted) | 7.5M | 51.84M | 28.34M | 850.3M |
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.